Ortho Clinical Diagnostics (OCDX) Stock Price, News & Analysis

Company Overview

Ortho Clinical Diagnostics Holdings plc provides in-vitro diagnostics solutions to the clinical laboratory and transfusion medicine communities worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company is also involved in the provision of contract manufacturing and orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. Ortho Clinical Diagnostics Holdings plc was founded in 1939 and is headquartered in Raritan, New Jersey.

Key Stats

• Today's Range: $17.63 to $17.63
• 50-Day Range: $17.63 to $17.63
• 52-Week Range: $16.04 to $22.99
• Volume: 5,400 shs
• Average Volume: 1.24 million shs
• Market Capitalization: $3.92 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OCDX Stock Analysis - Frequently Asked Questions

How were Ortho Clinical Diagnostics' earnings last quarter?

Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) announced its earnings results on Wednesday, November, 3rd. The company reported $0.21 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.07. The firm earned $522.50 million during the quarter, compared to analyst estimates of $485.36 million. Ortho Clinical Diagnostics had a negative net margin of 0.02% and a positive trailing twelve-month return on equity of 41.71%.
Read the conference call transcript.

When did Ortho Clinical Diagnostics IPO?

Ortho Clinical Diagnostics (OCDX) raised $1.5 billion in an initial public offering on Thursday, January 28th 2021. The company issued 70,000,000 shares at a price of $20.00-$23.00 per share. J.P. Morgan, BofA Securities, Goldman Sachs, Barclays and Morgan Stanley acted as the underwriters for the IPO and Citigroup, Credit Suisse, UBS Investment Bank, Evercore ISI, Piper Sandler, ING, Macquarie Capital, Nomura, TCG Capital Markets, Drexel Hamilton, H.C. Wainwright & Co., Ramirez & Co. and Siebert Williams Shank were co-managers.

What other stocks do shareholders of Ortho Clinical Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ortho Clinical Diagnostics investors own include Meta Platforms (META), WPP (WPP), Garmin (GRMN), Li Auto (LI), Advanced Micro Devices (AMD), Kinsale Capital Group (KNSL) and

Company Calendar

• Last Earnings: 11/03/2021
• Today: 7/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic Substances
• Sub-Industry: N/A
• Current Symbol: NASDAQ:OCDX
• CIK: 1828443
• Web: www.orthoclinicaldiagnostics.com
• Phone: 908-218-8000
• Fax: N/A
• Employees: 4,800
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 21.77
• P/E Growth: 1.66
• Net Income: -$54.30 million
• Net Margins: -0.02%
• Pretax Margin: 1.38%
• Return on Equity: 41.71%
• Return on Assets: 5.10%

Debt

• Debt-to-Equity Ratio: 4.91
• Current Ratio: 1.89
• Quick Ratio: 1.29

Sales & Book Value

• Annual Sales: $2.04 billion
• Price / Sales: 1.92
• Cash Flow: $2.28 per share
• Price / Cash Flow: 7.73
• Book Value: $1.99 per share
• Price / Book: 8.86

Miscellaneous

• Outstanding Shares: 222,585,000
• Free Float: N/A
• Market Cap: $3.92 billion
• Optionable: Not Optionable
• Beta: 1.32